NucalaActive Ingredient(s): Mepolizumab
FDA Approved: * November 4, 2015
Pharm Company: * GLAXOSMITHKLINE LLC
Mepolizumab, sold under the brand name Nucala, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis, and hypereosinophilic syndrome (HES). It recognizes and blocks interleukin-5 (IL-5), a signalling protein of the immune system. The most common side effects include headache, injection site reactions, and back pain. Contents 1 Medical uses 2 Side effects 3 Overdose 4 Interactions 5 Pharmacol... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.
Nucala 100 mg/ml Subcutaneous Injection, SolutionNDC: 0173-0892
Nucala 40 mg/.4ml Subcutaneous Injection, SolutionNDC: 0173-0904
Nucala 100 mg/ml Subcutaneous Injection, Powder, for SolutionNDC: 12064-018
Glaxosmithkline Manufacturing Spa